Pascale Cony-Makhoul
Overview
Explore the profile of Pascale Cony-Makhoul including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1292
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beauverd Y, Ianotto J, Thaw K, Sobas M, Sadjadian P, Curto-Garcia N, et al.
Leukemia
. 2025 Mar;
PMID: 40074852
Essential thrombocythemia (ET) and polycythemia vera (PV) are rare in adolescent and young adult (AYA). These conditions, similar to those in older patients, are linked with thrombotic complications and the...
2.
Sesques P, Kirkwood A, Kwon M, Rejeski K, Jain M, Di Blasi R, et al.
J Hematol Oncol
. 2024 Aug;
17(1):61.
PMID: 39107847
Autologous anti-CD19 chimeric antigen receptor (CAR) T cells are now used in routine practice for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Severe (grade ≥ 3) cytokine release syndrome (CRS) and...
3.
Saugues S, Lambert C, Daguenet E, Roth-Guepin G, Huguet F, Cony-Makhoul P, et al.
Haematologica
. 2024 May;
109(9):2893-2907.
PMID: 38695126
In chronic myeloid leukemia, the identification of early molecular predictors of stable treatment-free remission (TFR) after tyrosine kinase inhibitor (TKI) discontinuation is challenging. The predictive values of residual disease (BCR::ABL1...
4.
Durot E, Roos-Weil D, Chauchet A, Decroocq J, Di Blasi R, Gastinne T, et al.
Blood
. 2024 Apr;
143(26):2804-2807.
PMID: 38669635
Histologic transformation of Waldenström macroglobulinemia (HT-WM) carries a poor prognosis with standard treatments. Here, we report the first series of HT-WM treated with chimeric antigen receptor T cells showing a...
5.
Ghesquieres H, Cherblanc F, Belot A, Micon S, Bouabdallah K, Esnault C, et al.
Blood Adv
. 2023 Oct;
8(2):296-308.
PMID: 37874913
Real-world data (RWD) are essential to complement clinical trial (CT) data, but major challenges remain, such as data quality. REal world dAta in LYmphoma and Survival in Adults (REALYSA) is...
6.
Balsat M, Alcazer V, Etienne G, Huguet F, Berger M, Cayssials E, et al.
Leuk Res
. 2023 May;
130:107308.
PMID: 37230027
Accelerated phase (AP) CML at onset and have poorer prognosis than CP-CML. We hypothesize that off-license use of second generation TKI (TKI2) as front-line therapy might counterbalance this poor prognosis,...
7.
Dulucq S, Rigal-Huguet F, Nicolini F, Cony-Makhoul P, Escoffre-Barbe M, Gardembas M, et al.
Br J Haematol
. 2023 Apr;
201(6):1116-1124.
PMID: 37004981
Molecular recurrence (MRec) occurs in about half of all patients with chronic myeloid leukaemia (CML) who discontinue tyrosine kinase inhibitors (TKI) in sustained deep molecular response. A second TKI discontinuation...
8.
Belot A, Camus V, Portugues C, Paget J, Chartier L, Cony-Makhoul P, et al.
Br J Haematol
. 2023 Feb;
201(5):857-864.
PMID: 36813551
In the era of immunochemotherapy, data on the long-term prognosis of elderly patients diagnosed with a diffuse large B-cell lymphoma (DLBCL) are scarce. In this population and on the longer...
9.
Dumontet C, Demangel D, Galia P, Karlin L, Roche L, Fauvernier M, et al.
Am J Hematol
. 2023 Jan;
98(2):264-271.
PMID: 36588407
Familial forms of monoclonal gammopathy, defined as multiple myeloma (MM) or Monoclonal Gammopathy of Undetermined Significance (MGUS), are relatively infrequent and most series reported in the literature describe a limited...
10.
Lebecque B, Bourgne C, Munje C, Berger J, Tassin T, Cony-Makhoul P, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230624
RNA splicing factors are frequently altered in cancer and can act as both oncoproteins and tumour suppressors. They have been found mutated or deregulated, justifying the growing interest in the...